; (B) representatives from medical professional societies that specialize in the care of adults and pediatrics with cardiomyopathy; and (C) representatives from other relevant Federal agencies. (c) Cardiomyopathy defined For purposes of this section, the term cardiomyopathy means a heart disease that affects the heart’s muscle (myocardium)— (1) the symptoms of which may vary from case to case, including— (A) cases in which no symptoms are present (asymptomatic); and (B) cases in which there are symptoms of a progressive condition that may result from an impaired ability of the heart to pump blood, such as fatigue, irregular heartbeats (arrhythmia), heart failure, and, potentially, sudden cardiac death; and (2) the recognized types of which include dilated, hypertrophic, restrictive, arrhythmogenic right ventricular dysplasia, and left ventricular non-compaction. . (b) Federal working group (1) In general Not later than one year after the date of the enactment of this Act, the Secretary of Health and Human Services shall convene an interdisciplinary working group for the purpose of expanding cardiomyopathy research. (2) Duties The working group shall— (A) develop a research strategy to address the gaps in knowledge on the molecular and genetic causes of cardiomyopathy in children; (B) identify approaches that could result in the development of preventive and disease-directed therapies specific to pediatric car­di­o­my­op­a­thies and heart failure; and (C) explore novel clinical trial methodologies and end points in an effort to optimize successful completion of clinical trials in this rare patient population. (3) Membership The Secretary shall appoint to the working group members representing a range of stakeholders outside of the Federal Government with subject matter expertise relating to cardiomyopathy, including— (A) pediatric cardiologists with expertise in the diagnosis and treatment of children with cardiomyopathies and heart failure and clinical trials related to the pediatric population